Literature DB >> 10840156

Peroxiredoxin I expression in oral cancer: a potential new tumor marker.

T Yanagawa1, S Iwasa, T Ishii, K Tabuchi, H Yusa, K Onizawa, K Omura, H Harada, H Suzuki, H Yoshida.   

Abstract

This study investigates the applicability of the novel antioxidant protein, peroxiredoxin (Prx) I as a marker for tumor status in oral squamous cell carcinoma (SCC). Samples from 53 patients with SCC in the oral cavity were examined by immunohistochemistry. Correlations between the expression level of Prx I and proliferating cell nuclear antigen (PCNA), the clinical features of tumors, and their histopathological classifications were statistically analyzed. Cases exhibiting low Prx I expression level included significantly more with larger tumor mass cases (T-category, P=0.004), positive lymph node metastasis (N-category, P=0.015), advanced stage (P=0.002), and poorly differentiated cells (P=0.020). There was no significant difference between Prx I expression and the other indices.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10840156     DOI: 10.1016/s0304-3835(00)00434-1

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  40 in total

1.  Mutator genes for suppression of gross chromosomal rearrangements identified by a genome-wide screening in Saccharomyces cerevisiae.

Authors:  Stephanie Smith; Ji-Young Hwang; Soma Banerjee; Anju Majeed; Amitabha Gupta; Kyungjaem Myung
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-07       Impact factor: 11.205

2.  T-LAK cell-originated protein kinase (TOPK) phosphorylation of Prx1 at Ser-32 prevents UVB-induced apoptosis in RPMI7951 melanoma cells through the regulation of Prx1 peroxidase activity.

Authors:  Tatyana A Zykova; Feng Zhu; Tatyana I Vakorina; Jishuai Zhang; Lee Ann Higgins; Darya V Urusova; Ann M Bode; Zigang Dong
Journal:  J Biol Chem       Date:  2010-07-20       Impact factor: 5.157

3.  Prognostic significance of peroxiredoxin 1 and ezrin-radixin-moesin-binding phosphoprotein 50 in cholangiocarcinoma.

Authors:  Ponlapat Yonglitthipagon; Chawalit Pairojkul; Yaovalux Chamgramol; Alex Loukas; Jason Mulvenna; Jeffrey Bethony; Vajarabhongsa Bhudhisawasdi; Banchob Sripa
Journal:  Hum Pathol       Date:  2012-03-24       Impact factor: 3.466

4.  Proteome analysis of the effects of sorafenib on human hepatocellular carcinoma cell line HepG2.

Authors:  Aili Suo; Mingxin Zhang; Yu Yao; Lingmin Zhang; Chen Huang; Kejun Nan; Wanggang Zhang
Journal:  Med Oncol       Date:  2011-07-07       Impact factor: 3.064

5.  Cell specific expression of peroxiredoxins in human lung and pulmonary sarcoidosis.

Authors:  V L Kinnula; S Lehtonen; R Kaarteenaho-Wiik; E Lakari; P Pääkkö; S W Kang; S G Rhee; Y Soini
Journal:  Thorax       Date:  2002-02       Impact factor: 9.139

6.  Nrf2-peroxiredoxin I axis in polymorphous adenocarcinoma is associated with low matrix metalloproteinase 2 level.

Authors:  J M Brod; Ana Paula Dias Demasi; V A Montalli; L N Teixeira; C Furuse; M C Aguiar; A B Soares; M Sperandio; V C Araujo
Journal:  Virchows Arch       Date:  2017-08-28       Impact factor: 4.064

7.  Peroxiredoxin 1 stimulates secretion of proinflammatory cytokines by binding to TLR4.

Authors:  Jonah R Riddell; Xiang-Yang Wang; Hans Minderman; Sandra O Gollnick
Journal:  J Immunol       Date:  2009-12-16       Impact factor: 5.422

8.  ILK and PRDX1 are prognostic markers in squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder.

Authors:  Jinghe Li; Zhu-Lin Yang; Xuebao Ren; Qiong Zou; Yuan Yuan; Lufeng Liang; Meigui Chen; Senlin Chen
Journal:  Tumour Biol       Date:  2012-10-13

9.  Specific expression profile and prognostic significance of peroxiredoxins in grade II-IV astrocytic brain tumors.

Authors:  Sally Järvelä; Immo Rantala; Alejandra Rodriguez; Heini Kallio; Seppo Parkkila; Vuokko L Kinnula; Ylermi Soini; Hannu Haapasalo
Journal:  BMC Cancer       Date:  2010-03-22       Impact factor: 4.430

10.  Peroxiredoxin 1 has an anti-apoptotic role via apoptosis signal-regulating kinase 1 and p38 activation in mouse models with oral precancerous lesions.

Authors:  Jianfei Zhang; Xinying Jing; Wenwen Niu; Min Zhang; Lihua Ge; Congcong Miao; Xiaofei Tang
Journal:  Oncol Lett       Date:  2016-06-01       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.